MedTrace Logo

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

NCT06312020 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

Conditions

  • Sjogren's Syndrome

Interventions

DRUG

HZN-1116

Subcutaneous Administration

DRUG

Placebo

Subcutaneous Administration

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-09
Primary Completion
2026-04-28
Completion
2026-04-28
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Austria
  • Chile
  • Colombia
  • France
  • Germany
  • Hungary
  • Italy
  • Mexico
  • Poland
  • Portugal
  • Spain
  • Switzerland
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06312020 on ClinicalTrials.gov